Tue.Jun 25, 2024

article thumbnail

AbbVie's Duopa successor in Parkinson's rejected again after FDA flags third-party manufacturer issues

Fierce Pharma

A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established fo | A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established formulation of carbidopa and levodopa.

FDA 258
article thumbnail

How to Increase Sales in a Medical Field

David Bagga

Medical Device Sales Academy How to Increase Sales in a Medical Field Here are some of the ways that contribute towards increasing medical sales: 1. Get in-depth Product Knowledge A thorough understanding of your products is crucial in medical deals. This includes the technical specifications, clinical applications, and benefits. Attend training sessions, read product manuals, […] The post How to Increase Sales in a Medical Field appeared first on.

Medical 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo Nordisk wins approval in China for GLP-1 obesity drug Wegovy

Fierce Pharma

On the market for three years in China, Novo Nordisk’s diabetes drug Ozempic (semaglutide) is racing toward blockbuster sales in the world’s second most populous country. | China’s National Medical Products Administration (NMPA) has blessed Novo Nordisk's Wegovy with marketing approval to treat people with a body mass index (BMI) of at least 30 or between 27 and 30 for those with one weight-related risk factor.

Sales 241
article thumbnail

The tactical trap in pharma CX – and how to avoid it

Dominic Tyer

Customer experience (CX) is not a new discipline for pharma, but it does continue to provide the industry with growing pains

Pharma 130
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Drugmakers dig in their heels amid FTC's latest patent crackdown. What happens next?

Fierce Pharma

In the U.S. Federal Trade Commission’s (FTC) latest campaign against what the agency views as “junk” drug patents listed at the FDA, drugmakers have decided not to play ball. | In the U.S. Federal Trade Commission’s latest campaign against what the agency views as “junk” drug patent listings in the FDA’s database, drugmakers have decided not to play ball.

FDA 233
article thumbnail

Ahead of its upcoming decision date, a competitor takes aim at KarXT

PharmaVoice

The FDA isn’t slated to render a decision about BMS and Karuna’s potential breakthrough schizophrenia med until September — but a biotech is already hoping to be hot on its heels.

FDA 114

More Trending

article thumbnail

New multiple sclerosis treatment option granted in EU

European Pharmaceutical Review

The European Commission has approved the first twice-yearly injection for relapsing and primary progressive multiple sclerosis (RMS and PPMS). Roche highlighted that as a 10-minute injection, OCREVUS ® (ocrelizumab) subcutaneous has the same twice-yearly schedule as the intravenous (IV) infusion, which was the first therapeutic to be approved for both RMS and PPMS.

Medicine 111
article thumbnail

Glenmark recalls 114 batches of low potassium drug in the US over potentially deadly hyperkalemia risk

Fierce Pharma

While patients with low potassium often need medication to boost levels of the electrolyte in the body, too much of a good thing can cause serious health concerns. | Glenmark Pharmaceuticals on Tuesday said it’s recalling 114 batches of 750mg potassium chloride extended-release capsules thanks to failed dissolution of the product. Failed dissolution of the capsules could cause patients to develop heightened potassium levels, also known as hyperkalemia, which can result in irregular heartbeat.

article thumbnail

Can Moderna’s COVID-flu combo shot improve flagging vaccination rates?

PharmaVoice

A COVID and flu duo could ease manufacturing and administration, potentially driving higher vaccination rates, said Moderna’s VP of North American medical affairs.

article thumbnail

AstraZeneca's Imfinzi counts a trial win in bladder cancer, a miss in lung cancer

Fierce Pharma

AstraZeneca’s Imfinzi can’t have it all. | While the PD-L1 inhibitor posted a clinical win in muscle-invasive bladder cancer, it also chalked up a failure in early-stage non-small cell lung cancer.

186
186
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Illumina Spin-Off Now Complete, Grail Sets Out on Its Own on the Public Markets

MedCity News

Liquid biopsy company Grail is now an independent, publicly traded company. While the separation from Illumina ends a protracted antitrust battle, Grail is still in the early stages of a long-term strategy to win regulatory validation and payor coverage for its multi-cancer early detection test. The post Illumina Spin-Off Now Complete, Grail Sets Out on Its Own on the Public Markets appeared first on MedCity News.

Marketing 108
article thumbnail

After IBD wins, J&J's Tremfya misses the mark in giant cell arteritis

Fierce Pharma

As other immunology players make inroads into the giant cell arteritis (GCA) arena, one of Johnson & Johnson’s top-grossing medicines, Tremfya, has come up short in the disease. | As other immunology players make inroads into the giant cell arteritis arena, one of Johnson & Johnson’s top-grossing medicines, Tremfya, has come up short in the disease.

Medicine 140
article thumbnail

Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine

Pharmaceutical Technology

Novavax has sought EMA approval for its updated JN.1 Covid-19 vaccine, NVX-CoV2705, for people aged 12 years and above.

128
128
article thumbnail

Pomelo Care Secures $46M To Increase Access to Maternal Health

MedCity News

Pomelo Care’s $46 million Series B funding round was led by existing investors First Round Capital and a16z and included participation from Stripes, Box Group, Operator Partners and SV Angel. The post Pomelo Care Secures $46M To Increase Access to Maternal Health appeared first on MedCity News.

99
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Novo Nordisk invests $4.1bn in manufacturing facility in NC

Pharmaceutical Technology

Novo Nordisk has unveiled a significant investment plan, committing $4.1bn to construct a second fill and finishing facility in Clayton.

article thumbnail

Empowering Independence: The Rising Role of MLTSS in Medicaid Evolution

MedCity News

Managed long-term services and supports (MLTSS) are emerging as essential lifelines for transformation. The post Empowering Independence: The Rising Role of MLTSS in Medicaid Evolution appeared first on MedCity News.

article thumbnail

Mistrust in healthcare is hitting clinical trial enrolment

pharmaphorum

A survey of pharma industry executives has found that a third of them believe mistrust in the healthcare system has become a significant barrier to getting a diverse range of people to sign up for clinical trials.

article thumbnail

Meet The Startup That Gives Consumers Access to 100+ Lab Tests For $500 Per Year

MedCity News

Function Health, a membership-based platform that gives consumers access to more than 100 different lab tests, closed a Series A financing round that brought its total funding to date to $53 million. The round was led by Andreessen Horowitz and included a slew of celebrity investors, including Matt Damon, Zac Efron, Blake Griffin and Colin Kaepernick.

98
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug

Pharmaceutical Technology

Merck’s decision follows the independent committee's analysis that the trial is unlikely to meet its primary endpoints.

98
article thumbnail

Decoding the Digital Footprint of Healthcare Professionals: A Roadmap for Pharma Marketers

MedCity News

Knowing where healthcare professionals are online, their preferred platforms, and what they do there is crucial for pharma marketers. The post Decoding the Digital Footprint of Healthcare Professionals: A Roadmap for Pharma Marketers appeared first on MedCity News.

article thumbnail

Merck cans head and neck cancer drug once hailed as big hope

pharmaphorum

Two years ago, Merck KgAA was talking up xevinapant as a leap forward in head and neck cancer and one of the brightest stars in its late-stage pipeline, Now, the drug has been abandoned after failing a phase 3 trial.The TrilynX study was testing xevinapant with chemoradiotherapy in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), but according to an interim look at the data was unlikely to meet its goal of extending event-free survival.

Patients 103
article thumbnail

Pharma pulse 6/25/24: Novo Nordisk Invests $4.1 billion to Expand US Manufacturing, Improving the Efficacy of Genetic Medicines & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 105
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

The future of fertility and the vaginal microbiome

pharmaphorum

In a new episode of the pharmaphorum podcast - recorded back in March, during Women’s History Month - web editor Nicole Raleigh spoke with Johan van Hylckama Vlieg, co-founder and chief scientific officer of Freya Biosciences, a Series A-financed, clinical stage, microbial immunotherapy company in women’s health, discussing the role of the vaginal microbiome in fertility, before he was due to speak at the first-of-its-kind Microbes in Women’s Health Congress in Copenhagen.

103
103
article thumbnail

A Complete Guide to the OCR Ruling

Penrod

A Brief Background of the Original OCR Ruling In 2022, the Department of Health and Human Services Office for Civil Rights issued the original OCR ruling. This bulletin laid out specific guidelines on the use of online tracking technologies on mobile applications and websites belonging to HIPAA-regulated agencies. Primarily, the original OCR ruling defined what online trackers are and their uses on sites and apps.

article thumbnail

Young adults regret health decisions based on bad info

pharmaphorum

Almost half of young adults who participated in a UK survey said they had made a health decision they regret based on misinformation

105
105
article thumbnail

Onboard with Trust: Employee Experience During the First 90 Days

ALULA

E X is t he sum total of all interactions employees have with people , processes, technologies , and their physical working environment. Done properly, a mature and effective EX can boost engagement and productivity, as well as cut down on costly attrition.

52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Oral ketamine set for pivotal trials in resistant depression

pharmaphorum

Oral ketamine from Douglas Pharma shows efficacy in phase 2 treatment-resistant depression trial and will move into pivotal trials

Pharma 105
article thumbnail

EXO Biologics CEO Discusses Innovation in Developing Exosome Therapies

PharmExec

Hugues Wallemacq, CEO of EXO Biologics, discusses the company's innovative approach to developing scalable and GMP-compliant exosome therapies and ambitious plans to reshape the global therapeutic landscapes.

52
article thumbnail

AstraZeneca’s Imfinzi fails adjuvant trial in lung cancer

pharmaphorum

AstraZeneca’s hopes of positioning Imfinzi as a post-surgery therapy for people with early-stage NSCLC have taken a knock

104
104
article thumbnail

Advancing Bispecific Biologic Therapies for Solid Tumors and Blood Cancers

PharmExec

In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses how AbbVie is advancing the development of bispecific biologic therapies in both solid tumors and blood cancers.

52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A